Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is a novel staging modality for prostate cancer (PCa) patients with a high positive predictive value for lesions within and outside of the prostate. To assess the ability of the maximum standardized uptake value (SUVmax) at PSMA PET/CT to predict adverse pathology at radical prostatectomy (RP).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ken Herrmann
The Global Theranostics Access Gap: Real-World Disparities in PSMA PET/CT and 177Lu-PSMA Therapy Between Centers in Brazil and Europe.
Real-world disparities in access to PSMA-targeted theranostics are poorly characterized. We compared waiting times for PSMA PET/CT and 177Lu-PSMA therapy between centers in Brazil and Europe. Methods: This retrospective multicenter study included 91 patients (50 from Brazil, 41 from Europe) treated with 177Lu-PSMA. Outcomes were days from request to PSMA PET/CT completion (diagnostic access) and days from request to first therapy dose (therapeutic access).
Correlation of intraprostatic lesional SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy
Abstract Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is a novel staging modality for prostate cancer (PCa) patients with a high positive predictive value for lesions within and outside of the prostate. To assess the ability of the maximum standardized uptake value (SUVmax) at PSMA PET/CT to predict adverse pathology at radical prostatectomy (RP).
The Global Theranostics Access Gap: Real-World Disparities in PSMA PET/CT and 177 Lu-PSMA Therapy Between Centers in Brazil and Europe
DISCUSSION To our knowledge, this is the first multicenter real-world analysis quantifying disparities in both diagnostic and therapeutic access to PSMA-targeted theranostics between Brazil and Europe. Our findings reveal a striking asymmetry within the theranostic pathway: while PSMA PET/CT access is comparable (median, 17.5 d vs. 19.0 d), access to radiopharmaceutical therapy is profoundly delayed in Brazil (median, 59.0 d vs. 21.0 d).
Diagnostic value of [ 68 Ga]Ga-FAPI-46 PET in comparison to [ 18 F]FDG PET in triple-negative breast cancer and potential for theranostic application
|
By Alina Küper, Anja Welt, Rainer Hamacher, Tristan T. Demmert, Alexandros A. Moraitis, Loic Djaileb, Robert D. Seifert, Lale Umutlu, Martin Schuler, Ken Herrmann, Wolfgang Peter Fendler, Sherko Kümmel, David Kersting, Ieva Ciuciulkaite, Sofia Carrilho Vaz, Ilektra Antonia Mavroeidi, Kim Magaly Pabst
|
Nature
Verified
Abstract This single-center subgroup analysis of a prospective trial (NCT04571086) at University Hospital Essen investigated tumor uptake and detection rates of [68Ga]Ga-FAPI-46- versus [18F]FDG PET in triple-negative breast cancer (TNBC) patients undergoing initial or follow-up staging. Lesions were recorded across anatomical regions, with detection efficacy, uptake values, tumor-to-liver ratios, and tumor volumes assessed. 22 patients were included (initial- n = 10, follow-up staging n = 12).
Update to “Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy”
In the article “Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy” (J Nucl Med. 2024;65:71–78), it was identified that calibration factors applied to patients from two contributing sites (Münster and Munich) required correction.
Update to “Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy”
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
From Anatomy to Theranostics: Toni Choueiri Talks with Ken Herrmann About the Evolution of Genitourinary Oncology
Toni K. Choueiri, MD, is the director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, coleader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. He is the medical director of international strategic initiatives and past president of the medical staff at Dana-Farber Cancer Institute.
APCCC 2026: Beyond PSMA: New Theranostic Targets Approaching near Term Clinical Implementation
(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a radioligand and radionuclide therapy in advanced prostate cancer session and a presentation by Dr. Ken Herrmann discussing new theranostic targets approaching near term clinical implementation.
From Anatomy to Theranostics: Toni Choueiri Talks with Ken Herrmann About the Evolution of Genitourinary Oncology
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [ 177 Lu] Lu-PSMA-617 (ANZUP1901)
Keywords Metastatic prostate cancer PSMA-PET Total tumor volume Interim response Enzalutamide 177LuPSMA-617 What does this study add? This ENZA-p trial sub-study is the first prospective trial to show that prostate-specific membrane-antigen positron emission tomography (PSMA-PET) total tumor volume at 3 mos after commencing enzalutamide or enzalutamide plus 177LuPSMA-617 is prognostic for overall survival.
Efficacy of [18F]PSMA-1007 PET/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Metaanalysis
RESULTS Our search identified 287 articles, of which 268 were excluded, 164 through title/abstract screening and 104 through full-text screening. In the title/abstract screening, 108 studies were excluded because they were not clinical trials, 2 because the language of the publication was not English, 38 because they were performed in the recurrent setting (relapse/biochemical recurrence), and 16 because they used a tracer other than [18F]PSMA-1007.
α-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer
More effective treatments for metastatic prostate cancer (mPC) are needed as disease progression remains universal. 177Lu-PSMA-617 radiopharmaceutical therapy (RPT)—Pluvicto (Novartis)—was first approved for the treatment of castration-resistant prostate cancer (PC) based on the landmark VISION trial (1). Although Pluvicto is the “poster child” of RPT, the median overall survival benefit is modest at 4 mo (1).
Resisting RECIST: PSMA PET and Regulatory Change in Prostate Cancer
RECIST was developed in 2000 by the National Cancer Institute, European Organization for Research and Treatment of Cancer, and National Cancer Institute of Canada, with revision to RECIST 1.1 in 2009 (1). RECIST guidelines have led to the development of criteria for measuring disease progression approved by regulators across the globe. Despite success in numerous cancers, prostate cancer presents particular challenges for RECIST because of its distinctive metastatic pattern.
Efficacy of [18F]PSMA-1007 PET/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Metaanalysis
RESULTS Our search identified 287 articles, of which 268 were excluded, 164 through title/abstract screening and 104 through full-text screening. In the title/abstract screening, 108 studies were excluded because they were not clinical trials, 2 because the language of the publication was not English, 38 because they were performed in the recurrent setting (relapse/biochemical recurrence), and 16 because they used a tracer other than [18F]PSMA-1007.
Exploring the role of targeted radiopharmaceutical treatment in NETs
In this episode of the Oncology Brothers podcast, we dived deep into the evolving treatment strategies for neuroendocrine tumors (NETs), focusing specifically on Peptide Receptor Radionuclide Therapy (PRRT). We were joined by two experts: Dr. Heloisa Soares, a medical oncologist specializing in NETs, and Prof. Ken Herrmann, a nuclear medicine physician with extensive experience in Europe.
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis
Keywords Prostate cancer Prostate-specific membrane antigen Positron emission tomography/computed tomography What does this study add? There is a need for harmonisation and integration of existing prostate-specific membrane antigen positron emission tomography/computed tomography reporting systems. New reporting standards enabling large-scale prospective data collection are required. This study establishes a foundation for a dynamic, living iterative reporting system.
Precision Medicine Is Critical for the Future of Oncology
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Precision Medicine Is Critical for the Future of Oncology
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Theranostics in Perspective: White Paper
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
Theranostics in Perspective: White Paper
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
MHSPC SETTING For about a decade, ADT monotherapy has no longer been the standard of care in patients with mHSPC (20,21,26). Several studies have demonstrated that combination therapies are able to improve OS compared with ADT monotherapy (Figs. 2 and 3) (26). ADT plus docetaxel was the first combination shown to improve outcomes for patients with mHSPC, especially in patients with high-volume disease (7–9).
Green Nuclear Medicine and Radiotheranostics
ENVIRONMENTAL IMPACT OF HOSPITAL-BASED MOLECULAR IMAGING DEPARTMENTS It is difficult to precisely quantify the contribution of nuclear medicine to the global environmental impact of health care. The overall health care carbon footprint contributes an average of approximately 5% of the national CO2 footprint (Fig. 1) (7). Estimates for 2014 range from 3.5% in India to 7.9% in the United States and 8.1% in The Netherlands (7). Hospital care is the top contributor, with 36% of GHG emissions.
From Scientist to Analyst to Strategist
Ken Herrmann, MD, MBA, from the Universitätsklinikum Essen (Germany), and Johannes Czernin, MD, from the David Geffen School of Medicine at UCLA, talked with Aharon (Ronny) Gal, PhD, about his career across a range of scientific, analytic, consulting, and leadership positions.
Advancing Tomorrow’s Cancer Medicines
Ken Herrmann, MD, MBA, from the Universitätsklinikum Essen (Germany), and Johannes Czernin, MD, from the David Geffen School of Medicine at the UCLA, talked with Jacob S. Van Naarden, executive vice president and president of Lilly Oncology for Eli Lilly and Company (Indianapolis, IN). In this role, Van Naarden oversees all aspects of oncology, from discovery through commercial development. He joined Lilly in 2019, when the company acquired Loxo Oncology, Inc.
Green Nuclear Medicine and Radiotheranostics
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
The Co-IMPACT Consortium: Integrating Prostate-specific Membrane Antigen Positron Emission Tomography and Radiotherapy in Prostate Cancer Care
aRadiation Oncology Tata Memorial Centre Homi Bhabha National Institute Mumbai India bDivision of Radiation Oncology, European Institute of Oncology, IRCCS Milan Italy cDepartment of Oncology and Hemato-oncology, University of Milan Milan Italy dDepartment of Radiation Oncology, Kantonsspital Aarau Aarau Germany eDepartment of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich Munich Germany fInstitute of Radiation Medicine (IRM), Helmholtz Zentrum München (HMGU)...
Tumor Dosimetry in PSMA Therapy: A VISION Substudy Analysis - Ken Herrmann
Read the Full Video Transcript Oliver Sartor: Hi, I'm Dr. Oliver Sartor. I'm here with UroToday. And a real pleasure to be able to welcome Ken Herrmann. I think Ken Herrmann is known to almost everybody in the theranostics field. He's the Chairman of the Department of Nuclear Medicine at the University Hospital Essen, Essen, Germany. And Ken, are you going to be talking to us about some tumor dosimetry? A really interesting substudy from the VISION trial. So I'd love to hear your perspective on this.
Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers
1 INTRODUCTION Neuroendocrine neoplasms (NEN) represent a diverse group of uncommon cancers arising from the diffuse endocrine system, most typically from gastroenteropancreatic (GEP) origins, and also from the bronchopulmonary system or thymus.1 NEN often produce symptoms due to tumour growth, visceral/vascular obstruction or inappropriate hormone hypersecretion, resulting in debilitating diarrhoea, nausea, flushing and pain; all of which have an impact on patients' quality of life and...
U.S. Imaging Costs
Michal Horný, PhD, MSc, a health services researcher and assistant professor of Health Policy and Management at the University of Massachusetts Amherst, talked with Ken Herrmann, MD, MBA, from the Universitätsklinikum Essen (Germany), and Johannes Czernin, MD, from the David Geffen School of Medicine at the UCLA, about a recent analysis of U.S. imaging costs.
Diagnostic Accuracy of [18F]FDG PET/MRI in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Metaanalysis
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann
Read the Full Video Transcript Oliver Sartor: Hi, I'm Dr. Oliver Sartor, and really a pleasure today to be able to welcome Ken Herrmann on UroToday, one of the leading lights in the world and chairman of the German Nuclear Medicine Department at Essen, a professor there. Welcome, Ken. Ken Herrmann: Thank you very much, Oliver. It's a great honor to be with one of the big godfathers of radionuclide therapy in a conversation, Oliver.
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann
Read the Full Video Transcript Oliver Sartor: Hi, I'm Dr. Oliver Sartor, and really a pleasure today to be able to welcome Ken Herrmann on UroToday, one of the leading lights in the world and chairman of the German Nuclear Medicine Department at Essen, a professor there. Welcome, Ken. Ken Herrmann: Thank you very much, Oliver. It's a great honor to be with one of the big godfathers of radionuclide therapy in a conversation, Oliver.
Diagnostic Accuracy of [18F]FDG PET/MRI in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Metaanalysis
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
[177Lu]Lu-DOTATATE May Resensitize Neuroendocrine Tumors to Hormonal Therapy: Initial Clinical Experience in Renal Carcinoid
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
[177Lu]Lu-DOTATATE May Resensitize Neuroendocrine Tumors to Hormonal Therapy: Initial Clinical Experience in Renal Carcinoid
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Kick-Starting Molecular Theranostics in Renal Cell Carcinoma
The treatment landscape of renal cell carcinoma (RCC) is rich and consists of multiple local and systemic options. However, the medical need differs broadly between localized and metastatic stages. The article by Hofman et al. in The Journal of Nuclear Medicine (1) reported successful development of a novel theranostic tracer in RCC patients.
SIRT was identified as dominant treatment strategy
Back to Journals » ClinicoEconomics and Outcomes Research » Volume 16 Authors Schwander B , Klesper K, Rossol S, Herrmann K, Zoellner YF Received 6 March 2024 Accepted for publication 17 May 2024 Published 6 June 2024 Volume 2024:16 Pages 483—492 DOI https://doi.org/10.2147/CEOR.S461798 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Giorgio Colombo Bjoern Schwander,1 Katharina Klesper,2 Siegbert Rossol,3...
Design Considerations in the PSMAfore Trial
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
Abstract [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) plus the standard of care (SoC) significantly improved overall survival and radiographic progression-free survival versus SoC alone in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer in the VISION trial. We evaluated the safety of additional cycles of 177Lu-PSMA-617 and the impact of longer observation time for patients receiving 177Lu-PSMA-617 plus SoC.
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
Abstract [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) plus the standard of care (SoC) significantly improved overall survival and radiographic progression-free survival versus SoC alone in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer in the VISION trial. We evaluated the safety of additional cycles of 177Lu-PSMA-617 and the impact of longer observation time for patients receiving 177Lu-PSMA-617 plus SoC.
Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
RESULTS All 30 enrolled patients received at least 1 cycle of 177Lu-PSMA-617 plus standard of care. In cycle 1, multiple-time-point dosimetry was performed in 29 patients—1 patient received 177Lu-PSMA-617 but was unable to tolerate the imaging procedures required for dosimetry because of intense bone pain. One patient underwent imaging at 24 h in cycle 2 for clinical reasons and then at 48 h in all subsequent cycles.
Predictive Modeling for 177Lu-PSMA-617 Therapy in Patients with mCRPC - Ken Herrmann
Read the Full Video Transcript Phillip Koo: Welcome to UroToday, and our coverage of ASCO 2023. We're very privileged to have with us Dr. Ken Herrmann from University of Essen, who's presenting data regarding a predictive model for Lutetium-177-PSMA. Thank you for joining us. Before we get into to the data that you're presenting, can we talk a little bit about what is a prognostic tool versus a predictive tool? Ken Herrmann: That's an excellent question. So the prognostic tool mainly says...
Tackling the Last Mile: A Major Component to Successfully Establish Radioligand Therapy - Ken Herrmann
Read the Full Video Transcript Phillip Koo: Hello, my name is Phillip Koo and welcome to UroToday. Today we have with us Dr. Ken Herrmann, who's the Chief of Nuclear Medicine at Essen in Germany, who's going to be speaking about a recent article his team published titled, Tackling the Last Mile: A Major Component to Successfully Established Radioligand Therapy. Thank you very much for joining us, Ken. Ken Herrmann: Thank you. I'm pleased to be here.
Advancing Clinical Trial Innovation in Pancreatic Cancer
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Leading in Urology and Pioneering in Social Media Outreach
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center
Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center Ken Herrmann, Luca Giovanella, Andrea Santos, Jonathan Gear, Pinar Ozgen Kiratli, Jens Kurth, Ana M. Denis-Bacelar, Roland Hustinx, Marianne Patt, Richard L. Wahl, Diana Paez, Francesco Giammarile, Hossein Jadvar, Neeta Pandit-Taskar, Munir Ghesani, Jolanta Kunikowska Journal of Nuclear Medicine Dec 2022, 63 (12) 1836-1843; DOI: 10.2967/jnumed.122.264321
More Accurate Imaging Is Not Stage Migration: Time To Move from “Hubble” to “Webb” in Hormone-sensitive Prostate Cancer
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ken
Contact Ken, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack